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Introduction

Pathophysiology

Malignant hyperthermia (MH) is a
potentially life threatening disorder that
occurs following exposure to certain
inhaled anesthetics such as halothane,
isoflurane, sevoflurane, desflurane,
enflurane, ether, and methoxyflurane
alone or in combination with the
depolarizing muscle relaxant,
succinylcholine (Seifert,, Wahr, Pace,
Cochrane, & Bagnola, 2014, p. 189).
Patients experiencing malignant
hyperthermia may progress to death if it
is not recognized and treated early.
Patient outcomes improve the earlier an
intervention is given. Malignant
hyperthermia is not a common condition
and, therefore, nurses are frequently
unfamiliar with the common signs,
symptoms, and treatments. Malignant
hyperthermia can occur in a variety of
settings where these medications are
used such as the operating room, post
anesthesia recovery unit (PACU),
emergency department, interventional
radiology, labor and delivery, intensive
care units, dental offices, and ambulatory
surgery centers such as surgery centers
and office based facilities, hence, nurses
of all specialties may encounter MH
(Hirshey Dirksen, Van Wicklin, Mashman,
Neiderer, & Merritt, 2013, p. 332).
Recurrent education and simulation with
staff that work with patients receiving
possible triggering agents would improve
patient outcomes when they are faced
with malignant hyperthermia
emergencies. The purpose of this
scholarly project is to provide education
to nurses regarding malignant
hyperthermia in hopes that it will
increase their knowledge on the subject
and prepare them for the medical
emergency of malignant hyperthermia.

Malignant hyperthermia is a rare,
autosomal dominant genetic disorder of
the skeletal muscle that causes a life
threatening hypermetabolic crisis. The
people who are susceptible to MH have a
gene mutation in the ryanodine receptor
subtype 1 (RYR-1) gene which is found
in all skeletal muscle. This gene encodes
the calcium ion channel in skeletal
muscle and is responsible for calcium
release within myocytes. The RYR-1 is
also the binding site for inhaled
anesthetics and dantrolene (Cain, Riess,
Gettrust, & Novalija, 2014, p. 302). When
triggering agents such as volatile
(inhaled) anesthetics and depolarizing
muscle relaxants are administered to an
individual with an abnormal RYR-1 gene,
there is a prolonged opening of the
altered RYR-1 receptor and an
uncontrolled intracellular calcium
release from the skeletal muscle
sarcoplasmic reticulum into the cytosol.
This causes a state of intense, sustained
skeletal muscle contraction and rigidity
which, in turn, causes increased
sympathetic activity, oxygen
consumption, and the production of
carbon dioxide and heat from the rapid
use of ATP (Hirshey Dirksen et al., 2013,
p. 331). The contracted cells eventually
deplete the oxygen and ATP and begin
anaerobic metabolism which produces
lactic acid and ultimately causes cellular
death and destruction. Potassium, as
well as other electrolytes (such as
calcium, phosphate, and magnesium),
creatine kinase(CK), and myoglobin then
leak into the bloodstream as a result of
the damaged cell membranes (Seifert et
al., 2014, p. 195-196).

Significance of Pathophysiology
The significance of the pathophysiology in MH is due to the fatal complications that can
occur as a result if it goes untreated. Hyperkalemia causes fatal cardiac dysrhythmias
such as ventricular fibrillation and ventricular tachycardia. Myoglobinemia causes
renal failure as the excessive CK and myoglobin released into the circulation blocks the
renal tubules. Other complications, many of which are fatal, from MH include liver
failure, compartment syndrome from profound muscle swelling, skeletal
muscle damage, mixed respiratory acidosis or metabolic acidosis, abnormal blood
coagulation and DIC, internal hemorrhage, neurologic injury, hyperthermia,
rhabdomyolysis, bowel ischemia, CHF, pulmonary edema, end organ damage, cardiac
collapse or arrest, and death (Hirshey Dirksen, et al., 2013, p. 333; Seifert et al., 2014,
p. 189). These clinical signs are results of the inability of the body to maintain the
increased metabolic demand during a malignant hyperthermia crisis.

Signs and Symptoms
The signs and symptoms of
malignant hyperthermia usually occur
within minutes or up to an hour after
the administration of the triggering
agent, however, if succinylcholine is
used in conjunction with an inhaled
anesthetic, the onset of symptoms is
generally quicker. It is possible that
MH may develop up to 36 hours after
exposure to the triggering agent. The
signs and symptoms of MH can present
in any sequence, but there are typically
three signs that manifest the earliest
(Cain et al., 2014. p. 302-303). The first
sign of MH is hypercarbia or an
unexplained, progressive increase in
carbon dioxide production. The ETCO2
can double or triple a normal
capnography value in MH. The next
signs that typically manifest are
masseter (jaw) muscle spasm and
sinus tachycardia. Other early signs
include flushed skin, dysrhythmias,
such as PVC’s and bigeminy, and
generalized muscle rigidity.
Hyperthermia is actually a late sign of
MH despite the name of this disorder.
The rapid increase in body
temperature can exceed 43.3° C [109°
F], and it can increase by 1° C to 2° C
[1.8° F to 3.6° F] every five minutes
(Seifert et al., 2014, p. 189). Other late
signs are metabolic acidosis, hypoxia,
mottled skin, cyanosis, coagulopathy,
left ventricular failure evidenced by
pulmonary edema, rales, and frothy
sputum, and brown, cola-colored urine
from rhabdomyolysis. Other possible
signs and symptoms of MH include
mixed respiratory acidosis, tachypnea,
sweating, myoglobinuria,
hyperkalemia, ventricular tachycardia,
and ventricular fibrillation (Stewart,
2014, p. 253-254). MH can recur
within 24 to 48 hours after the initial
event, so the patient with MH should
be monitored for recrudescence, which
is the recurrence of symptoms after a
period of remission (Hirshey Dirksen,
2013, p. 333).
Signs and Symptoms
• Hypercarbia
• Tachycardia
• Masseter spasm
• Flushed skin
• Cardiac dysrhythmias
• Generalized muscle rigidity
• Tachypnea
• Hyperthermia
• Hypoxia
• Acidosis
• Coagulopathy

Conclusion
lobortis temporibus in usu?

Implications for Nursing Care
The goal of treatment of malignant
hyperthermia is to reverse the
hypermetabolic state and prevent the
potentially lethal consequences of MH.
The likelihood of a positive outcome
after diagnosis of MH improves with
expeditious treatment. If MH is not
treated rapidly, the mortality rate is
high. The most effective treatment for
MH is the administration of dantrolene
sodium. The mortality rate from MH
used to be as high as 80%, but since the
discovery of dantrolene in 1975, it is
now down to 5% (Hirshey Dirksen et
al., 2013, p. 330). Dantrolene is a
specific ryanodine receptor antagonist
and reverses the MH related muscle
contractions by decreasing the calcium
in muscle cells (Seifert et al., 2014, p.
192). The longer time that elapses
between the onset of MH and the first
dose of dantrolene results in an
increase in complications associated
with MH. It is well known that the
preparation of dantrolene is difficult.
Some of the difficulties with dantrolene
preparation are that it requires large
quantities of diluents to be mixed with
large quantities of the medication and it
requires complicated medication
calculations. The required dose of
dantrolene is 2.5 mg/kg rapidly
through a large bore IV every 5 minutes
and repeat until symptoms subside or a
maximum dose of 30 mg/kg has been
reached. Dantrolene comes in 20 mg
vials and must be mixed with 60 ml
sterile water (Seifert et al., 2014, p.
192-194). For a patient who weighs
100 kg, the initial dose of dantrolene.

P

would be 250 mg. That would require 12.5
vials of dantrolene to be mixed and a total of
750 ml sterile water. If this medication
preparation must be done every five
minutes, it can become time consuming and
difficult to calculate. It may take several
nurses mixing dantrolene at the same time
to get the first critical dose in a timely
manner. In a rare situation like MH, this skill
is not second nature and must be practiced
to be effective in an emergency. Another
obvious treatment of MH is to stop the
volatile anesthetic and either abort the
procedure or switch to a non-triggering
anesthetic. An increase in oxygenation to
100% FIO2 will help prevent anaerobic
metabolism, and hyperventilation will
decrease the excess CO2 build up resulting
from MH (Seifert et al., 2014, p. 195). Also,
sodium bicarbonate can be given to treat
metabolic acidosis, and insulin and calcium
can be given to treat hyperkalemia (see
Figure 1). Nurses should be prepared to
start cooling measures immediately by
using cooling blankets, gastric lavage, body
cavity irrigation such as the surgical site,
and ice packs. Shivering should be avoided,
though, because it will increase the
metabolic state. The goal is to keep the
temperature of the patient with MH lower
than 39° C [102.2° F] (Cain et al., 2014. p.
302). Cardiac dysrhythmias should be
treated with normal ACLS medications, but
calcium channel blockers should not be
used because they interact with dantrolene
at the receptor site (Seifert et al., 2014, p.
196). After swift and appropriate treatment,
the patient with MH would hopefully revert
back to a normal metabolic state with no
complications.

Malignant hyperthermia is a very
rare occurrence and only occurs
approximately once in every 3,000 to
50,000 procedures where volatile
anesthetics are administered (Dirksen
et al., 2013, p. 330). It is of importance,
though, because it can progress quickly
to a life threatening situation and is a
medical emergency. Because it is rare,
many nurses are unprepared to care for
a patient experiencing MH. The specifics
about the signs and symptoms,
diagnosis, treatment, and location of
MH emergency supplies should be
reviewed frequently by personnel that
may encounter it (Hirshey Dirksen,
2013, p. 333). The areas where MH may
occur are vast which means nurses of
all specialties need to review this
information at a minimum of each year
to give the patient experiencing MH a
chance for the best outcome. Education
and simulation are integral parts of MH
preparedness.
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Figure 1. Medication doses and treatments for malignant hyperthermia. Reprinted from “CRISIS CONSIDERATIONS. Crisis
Management of Malignant Hyperthermia in the OR”, by P. C. Seifert, J. A. Wahr, A. B. Cochrane, and A. J. Bagnola, 2014, AORN
Journal, 100(2), p. 198. Copyright 2014 by Elsevier Inc. Reprinted with permission.

